Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors

M.D. Anderson Cancer Center

Status: Enrolling

Conditions: Parathyroid Gland Atypical Adenoma; Primary Hyperparathyroidism; Parathyroid Gland Carcinoma; Parathyroid Gland Adenoma

Treatments: Other: Laboratory Biomarker Analysis; Procedure: Biospecimen Collection

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT03039439

P30CA016672 (U.S. NIH Grant/Contract)

PA15-0928 (Other Identifier)

NCI-2018-01317 (Registry Identifier)

Details and patient eligibility

About

This trial studies molecular and immunohistochemical profiling of tumors in patients with parathyroid tumors. Studying molecular and immunohistochemical profiling of tumors may help doctors avoid inconsistencies in diagnosis, unnecessary or incomplete surgery, surgical morbidity, psychological stress, and inadequate follow up.

Full description

PRIMARY OBJECTIVES:

I. To determine the differences in clinical behavior and immunohistochemical (IHC) biomarkers between parathyroid carcinoma (PC), atypical neoplasm (AN) and parathyroid adenoma (PA).

II. To determine which potential genes can be used in patients with parathyroid tumors for diagnostic purposes.

OUTLINE:

Previously collected tumor tissue and blood samples are analyzed via immunohistochemical profiling for identifying potential genes showing molecular aberrations as other types of cancer.

Enrollment: 310 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient cohort for this study consists of all patients within the prospectively maintained parathyroid database within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center (MDACC) or from collaborating sites, with tissue or blood available from 1968-2015, previously consented for the use of the tissue for research purposes (via Protocols LAB 08-0034, PA11-0695 and LAB03-0320 or the appropriate external mechanism for collaborating sites).
• All patients with a known diagnoses of primary hyperparathyroidism (PHPT) operated/treated in the Department of Surgical Oncology of MDACC or at a collaborating site. Patients that have provided consent for the use of the tissue or blood for research purposes will then be considered for our study (via Protocol LAB03-0320 and LAB 08-0034 or the appropriate external mechanism for collaborating sites).
• All consented patients with known diagnoses of PHPT with a histopathological diagnosis of: parathyroid carcinoma, atypical parathyroid neoplasm or parathyroid adenoma. There will be no restrictions on age, gender, or ethnicity.
• Selected patients obtained through outside collaboration who meet the selection criteria for tissue availability and diagnostic suitability for inclusion in the study.

Exclusion criteria

• Patients without tissue available for analysis.

Trial design

310 participants in 1 patient group

Ancillary-Correlative (laboratory biomarker analysis)

Description:

Previously collected tumor tissue and blood samples are analyzed via immunohistochemical profiling for identifying potential genes showing molecular aberrations as other types of cancer.

Treatment:

Procedure: Biospecimen Collection

Other: Laboratory Biomarker Analysis